PIN71 The Potential Public Health Benefit of Pneumococcal Conjugate Vaccines in Kazakhstan

Simple item page
dc.contributor.authorNurgozhin, T.
dc.contributor.authorYermekbaeva, B.
dc.contributor.authorTopachevskyi, O.
dc.creatorT., Nurgozhin
dc.date.accessioned2017-12-14T08:50:28Z
dc.date.available2017-12-14T08:50:28Z
dc.date.issued2012-11-01
dc.description.abstractTo evaluate cost–effectiveness of pneumococcal vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV) compared with 13-valent pneumococcal conjugate vaccine (PCV-13) and no vaccination in Kazakhstan.
dc.identifierDOI:10.1016/j.jval.2012.08.1138
dc.identifier.citationT. Nurgozhin, B. Yermekbaeva, O. Topachevskyi, PIN71 The Potential Public Health Benefit of Pneumococcal Conjugate Vaccines in Kazakhstan, In Value in Health, Volume 15, Issue 7, 2012, Page A398
dc.identifier.issn10983015
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S1098301512028513
dc.identifier.urihttp://nur.nu.edu.kz/handle/123456789/2897
dc.relation.ispartofValue in Health
dc.rights.licenseCopyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.
dc.titlePIN71 The Potential Public Health Benefit of Pneumococcal Conjugate Vaccines in Kazakhstan
dc.typeArticle
dcterms.publisherValue in Health
elsevier.aggregationtypeJournal
elsevier.coverdate2012-11-01
elsevier.coverdisplaydateNovember 2012
elsevier.identifier.doi10.1016/j.jval.2012.08.1138
elsevier.identifier.eid1-s2.0-S1098301512028513
elsevier.identifier.piiS1098-3015(12)02851-3
elsevier.issue.identifier7
elsevier.issue.nameISPOR 15th Annual European Congress and ISPOR 5th Asia-Pacific Conference
elsevier.openaccess1
elsevier.openaccessarticletrue
elsevier.openaccessuserlicensehttp://www.elsevier.com/open-access/userlicense/1.0/
elsevier.openarchivearticletrue
elsevier.startingpageA398
elsevier.volume15

Files

Collections

Articles